7 completed, 6 unknown, 4 withdrawn, 3 terminated. 20 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 20 | Completed 7, Unknown 6, Withdrawn 4, Terminated 3 |
| Phase 2 | 8 | Completed 2, Terminated 2, Unknown 2, Withdrawn 2 |
Follow COVID: new trials by email Literature Review of COVID trials Research Report on COVID
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Pentoxifylline as Add on Therapy in COVID19 Patients Pentoxifylline, Placebo - COVID | Phase 1 / Phase 2 | Withdrawn | Sadat City University | 2022-11-13 | 2023-01-18 | |
| Combination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising Treatment for COVID-19 Infection- and Its Inflammatory Complications Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2) plus Aerosolized 13 cis retinoic acid - COVID | Phase 1 | Unknown | Kafrelsheikh University | 24 | 2021-07-01 | 2021-06-09 |
| Trial of Combination Therapy to Treat COVID-19 Infection Ivermectin, Doxycycline Hcl, Zinc - COVID, Covid-19 | Phase 1 | Completed | ProgenaBiome | 31 | 2020-12-09 | 2024-09-24 |
| Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients Ivermectin Injectable Solution, Injectable Placebo, Zinc - Coronavirus Infection, COVID | Phase 1 / Phase 2 | Unknown | Sohaib Ashraf | 180 | 2020-11-14 | 2021-02-17 |
| Remote Monitoring of Cancer Patients With Suspected Covid-19 Patient Status Engine - COVID, Oncology | Phase 1 | Unknown | The Christie NHS Foundation Trust | 30 | 2020-10-12 | 2021-02-11 |
| Maraviroc in Patients With Moderate and Severe COVID-19 Maraviroc - COVID | Phase 1 | Completed | Rhode Island Hospital | 9 | 2020-10-01 | 2024-04-29 |
| Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS) Defibrotide - COVID, Sars-CoV2 | Phase 1 | Completed | Gregory Yanik | 13 | 2020-10-01 | 2023-05-09 |
| Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation BM-Allo.MSC, Placebo - COVID | Phase 1 | Terminated | ImmunityBio, Inc. | 4 | 2020-08-03 | 2024-09-05 |
| Administration of Allogenic UC-MSCs as Adjuvant Therapy for Critically-Ill COVID-19 Patients Oseltamivir, Azithromycin, Umbilical Cord Mesenchymal Stem Cells - COVID, Pulmonary Infection | Phase 1 | Unknown | Universitas Indonesia | 40 | 2020-07-01 | 2020-07-07 |
| Therapeutic Vaccine Trial of COVID-19 for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Covax-19™ - COVID | Phase 1 | Unknown | GeneCure Biotechnologies | 32 | 2020-07-01 | 2020-06-11 |
| Monovalent Recombinant COVID19 Vaccine COVID19 vaccine, Saline - Coronavirus Infection, COVID | Phase 1 | Completed | Vaxine Pty Ltd | 40 | 2020-06-30 | 2022-03-02 |
| hCT-MSCs for COVID19 ARDS Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University., Placebo - COVID, Corona Virus Infection | Phase 1 / Phase 2 | Terminated | Joanne Kurtzberg, MD | 12 | 2020-06-18 | 2022-12-20 |
| Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome Mesenchymal Stromal Stem Cells - KI-MSC-PL-205 - ARDS, Human, COVID | Phase 1 | Completed | Uppsala University | 7 | 2020-06-17 | 2026-04-30 |
| A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19 APL-9, Vehicle Control - COVID, Covid-19 | Phase 1 / Phase 2 | Completed | Apellis Pharmaceuticals, Inc. | 72 | 2020-05-28 | 2022-03-23 |
| Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells Allogenic pooled olfactory mucosa-derived mesenchymal stem cells, Standard treatment according to the Clinical protocols - COVID, Covid-19 | Phase 1 / Phase 2 | Completed | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | 32 | 2020-05-11 | 2021-08-23 |
| Low Dose Radiotherapy in COVID-19 Pneumonia Low Dose Radiotherapy - COVID, SARS (Severe Acute Respiratory Syndrome) | Phase 1 / Phase 2 | Unknown | Shahid Beheshti University of Medical Sciences | 5 | 2020-05-04 | 2020-11-10 |
| Convalescent Plasma vs. Standard Plasma for COVID-19 Convalescent Plasma, Standard Donor Plasma - COVID | Phase 1 / Phase 2 | Terminated | Stony Brook University | 82 | 2020-04-08 | 2021-12-06 |
| Intermediate IND Severe Illness COVID-19 CP SARS-CoV-2 plasma - Severe Acute Respiratory Syndrome, COVID | Phase 1 | Withdrawn | Henry Ford Health System | 2020-04-07 | 2025-12-19 | |
| Adoptive Cell Transfer for the Immunotherapy of COVID-19 in Colombia Allogeneic NK transfer - COVID | Phase 1 / Phase 2 | Withdrawn | Universidad Nacional de Colombia | 2020-03-30 | 2021-05-05 | |
| A Study of ResCure™ to Treat COVID-19 Infection ResCure™ - COVID, Covid-19 | Phase 1 | Withdrawn | ProgenaBiome | 2020-01-01 | 2021-04-08 |
COVID-19 (11) · Coronavirus Infections (7) · Respiratory Distress Syndrome (4) · Severe Acute Respiratory Syndrome (4) · Acute Lung Injury (1) · Dyspnea (1) · Hematologic Neoplasms (1) · Lung Diseases, Interstitial (1) · Neoplasms (1) · Pneumonia (1) · Pneumonia, Viral (1)
Respiratory Tract Diseases (13) · Coronaviridae Infections (12) · Infections (12) · Lung Diseases (12) · Nidovirales Infections (12) · RNA Virus Infections (12) · Respiratory Tract Infections (12) · Virus Diseases (12) · Pneumonia (10) · Pneumonia, Viral (10) · Coronavirus Infections (5) · Respiration Disorders (5) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Lung Injury (1)
Ivermectin (2) · SARS-CoV-2 recombinant spike protein with delta inulin and CpG-ODN adjuvant vaccine (2) · Zinc (2) · Ascorbic Acid (1) · Azithromycin (1) · COVID-19 Serotherapy (1) · COVID-19 Vaccines (1) · Cholecalciferol (1) · Doxycycline (1) · Maraviroc (1) · Oseltamivir (1) · Pentoxifylline (1) · Radiotherapy (1) · Saline Solution (1) · Sodium Chloride (1)
ProgenaBiome (2) · Apellis Pharmaceuticals, Inc. (1) · GeneCure Biotechnologies (1) · Gregory Yanik (1) · Henry Ford Health System (1) · ImmunityBio, Inc. (1) · Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus (1) · Joanne Kurtzberg, MD (1) · Kafrelsheikh University (1) · Rhode Island Hospital (1) · Sadat City University (1) · Shahid Beheshti University of Medical Sciences (1) · Sohaib Ashraf (1) · Stony Brook University (1) · The Christie NHS Foundation Trust (1)
United States (9) · Australia (1) · Belarus (1) · Brazil (1) · Colombia (1) · Egypt (1) · Indonesia (1) · Iran (1) · Pakistan (1) · Sweden (1) · United Kingdom (1)
Sabine Hazan, MD (2) · Ahmad Ameri, Prof. (1) · Andrei Y Hancharou, Dr. (1) · David Gordon, MBBS, Ph.D (1) · Debra J Levan, DO (1) · Eduard A Dotsenko, Dr., prof. (1) · Elliott Bennett-Guerrero, MD (1) · Gregory Yanik, MD (1) · Ismail H Dilogo, MD, PhD (1) · Joanne Kurtzberg, MD (1) · John Radford (1) · Lingye Chen, MD (1) · M.Sc. Mahmoud Elkazzaz, M.Sc.Biochemistry (1) · Moneeb Ashraf, MBBS (1) · Muhammad Ashraf, PhD (1)
PMID 33870923, PMID 34013969, PMID 34488858, PMID 35135310, PMID 35413279, PMID 36734509, PMID 37162745, PMID 39702045